ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LQDA vs ABCL // DIVIDEND YIELD & FCF PAYOUT SAFETY

Liquidia Corporation (NASDAQ) VS. AbCellera Biologics Inc. (NASDAQ) • 15-METRIC TALLY: LQDA 8 — ABCL 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LQDA VS. ABCL) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LQDA ABCL SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -12.60% -20.50% +7.90 LQDA /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -0.99% -4.11% +3.12 LQDA /fcf-yield <GO>
Operating Margin -32.50% -60.00% +27.50 LQDA /operating-margins <GO>
Net Profit Margin -43.50% -60.00% +16.50 LQDA /net-margins <GO>
Revenue Growth (YoY) 180.00% 160.60% +19.40 LQDA /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 6.33 6.60 -0.27 ABCL /balance-sheet <GO>
Piotroski F-Score Quality 5/9 4/9 +1.00 LQDA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 52.5 49.0 +3.50 LQDA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta 0.90 — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 21.0x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $4.03B $3.97B $58.9M LQDA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LQDA REV ABCL REV LQDA GROSS % ABCL GROSS % LQDA FCF ABCL FCF
FY 2025 $158.3M $75.1M — — -$40.0M -$174.1M
FY 2024 $14.0M $28.8M 58.0% — -$98.4M -$187.0M
FY 2023 $17.5M $38.0M — — -$42.4M -$43.9M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LQDA // BETA 0.90
ABCL // BETA —